Granules India Q4 Review - Growth Momentum Sustains But Challenges Ahead: ICICI Direct

Granules India manufacturing facility. (image Company website)

Granules India Q4 Review - Growth Momentum Sustains But Challenges Ahead: ICICI Direct

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Despite Covid-19 impediments such as logistics disruption, raw material shortages and lower capacity utilisation, Granules India Ltd.'s Q4 revenue grew 33.2% YoY to Rs 799 crore driven by new launches and higher market share of existing products.

Finished dosage drugs grew 34% YoY to Rs 461 crore due to increased volumes.

Active pharmaceutical ingredients grew 9.1% to Rs 194 crore amid new customer additions.

Pharmaceutical formulation intermediates grew 85% to Rs 144 crore on a low base tracking increased market penetration and new customer additions.

Click on the attachment to read the full report:

ICICI Direct Granules India Q4FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.